Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA to review Akebia’s and Otsuka’s vadadustat for anemia resulting from chronic kidney disease

By Brian Buntz | June 1, 2021

Akebia/OtsukaFDA has accepted a new drug application (NDA) for the oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor vadadustat from Akebia Therapeutics (NSDQ:AKBA) and its partner Otsuka Pharmaceutical Co. (TYO:4578).

The two companies are pursuing the use of the drug to treat anemia resulting from chronic kidney disease.

The oral drug would offer patients more flexibility than anemia treatments known as Erythropoiesis-stimulating agents, which are injectable drugs that stimulate the bone marrow to produce red blood cells.

FDA has assigned the application a standard review and has set a Prescription Drug User Fee Act (PDUFA) target action date of March 29, 2022.

The agency is not intending on holding an Advisory Committee meeting for the application.

In a statement, Akebia CEO John P. Butler said the company looks “forward to working with the FDA” as it reviews the application. “In addition, we continue to collaborate with our partners to ensure we are well positioned to support a successful commercial launch of vadadustat, upon FDA approval,” Butler added.

The FDA’s NDA acceptance “highlights [Akebia’s and Otsuka’s] ongoing execution as well as our shared commitment to advancing vadadustat with the goal of bringing this novel therapeutic to patients as soon as possible, subject to regulatory approval,” said Kabir Nath, board member of Otsuka Pharmaceutical Co.

By the end of the year, the two companies also intend to file the Marketing Authorization Application for vadadustat with the European Medicines Agency.

In April, NEJM published a study concluding that vadudustat was noninferior to darbepoetin alfa in terms of cardiovascular safety and its ability to maintain hemoglobin concentrations in patients undergoing dialysis.

Fibrogen is pursuing FDA approval for roxadustat, which is a similar drug to vadadustat.


Filed Under: Drug Discovery and Development, Hematology, Nephrology/urology
Tagged With: Akebia Therapeutics, chronic kidney disease, Erythropoiesis-stimulating agents, FDA, Otsuka Pharmaceutical, vadadustat
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Pfizer-BioNTech
Pfizer and BioNTech forge new COVID-19 vaccine deal with U.S. government
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
GSK
GSK to invest £1 billion on infectious disease research
CB Therapeutics
CB Therapeutics hires new business development lead

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50